Fluicell AB (FLUI) - Total Assets
Based on the latest financial reports, Fluicell AB (FLUI) holds total assets worth Skr20.77 Million SEK (≈ $2.23 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Fluicell AB - Total Assets Trend (2014–2025)
This chart illustrates how Fluicell AB's total assets have evolved over time, based on quarterly financial data. Also see Fluicell AB (FLUI) market capitalisation for the company's overall valuation and market capitalisation.
Fluicell AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Fluicell AB's total assets of Skr20.77 Million consist of 41.1% current assets and 58.9% non-current assets. Review total liabilities of Fluicell AB to assess the company's total debt and financial obligations.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr2.26 Million | 12.2% |
| Accounts Receivable | Skr2.20 Million | 11.9% |
| Inventory | Skr3.04 Million | 16.4% |
| Property, Plant & Equipment | Skr445.00K | 2.4% |
| Intangible Assets | Skr10.43 Million | 56.5% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Fluicell AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Fluicell AB stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Fluicell AB's current assets represent 41.1% of total assets in 2025, a decrease from 94.5% in 2014.
- Cash Position: Cash and equivalents constituted 12.2% of total assets in 2025, down from 67.9% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 56.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 56.5% of total assets.
Fluicell AB Competitors by Total Assets
Key competitors of Fluicell AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
Fluicell AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.33 | 2.82 | 1.70 |
| Quick Ratio | 0.88 | 2.19 | 1.40 |
| Cash Ratio | 0.00 | 1.86 | 1.17 |
| Working Capital | Skr2.19 Million | Skr9.46 Million | Skr6.17 Million |
Fluicell AB - Advanced Valuation Insights
This section examines the relationship between Fluicell AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.29 |
| Latest Market Cap to Assets Ratio | 0.25 |
| Asset Growth Rate (YoY) | -27.6% |
| Total Assets | Skr18.48 Million |
| Market Capitalization | $4.64 Million USD |
Valuation Analysis
Below Book Valuation: The market values Fluicell AB's assets below their book value (0.25x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Fluicell AB's assets decreased by 27.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Fluicell AB (2014–2025)
The table below shows the annual total assets of Fluicell AB from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr18.48 Million ≈ $1.99 Million |
-27.57% |
| 2024-12-31 | Skr25.51 Million ≈ $2.75 Million |
+173.10% |
| 2023-12-31 | Skr9.34 Million ≈ $1.01 Million |
-70.60% |
| 2022-12-31 | Skr31.77 Million ≈ $3.42 Million |
+17.73% |
| 2021-12-31 | Skr26.98 Million ≈ $2.90 Million |
+8.66% |
| 2020-12-31 | Skr24.83 Million ≈ $2.67 Million |
+24.54% |
| 2019-12-31 | Skr19.94 Million ≈ $2.15 Million |
-23.24% |
| 2018-12-31 | Skr25.97 Million ≈ $2.80 Million |
+125.17% |
| 2017-12-31 | Skr11.54 Million ≈ $1.24 Million |
+315.68% |
| 2016-12-31 | Skr2.77 Million ≈ $298.63K |
+62.66% |
| 2015-12-31 | Skr1.71 Million ≈ $183.59K |
+2.04% |
| 2014-12-31 | Skr1.67 Million ≈ $179.92K |
-- |
About Fluicell AB
Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve sys… Read more